# Chongqing Precision Biotech Co., Ltd trials: 51 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 51 trials with Chongqing Precision Biotech Co., Ltd as lead sponsor, 27 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Chongqing Precision Biotech Co., Ltd: 51 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 51
- Recruiting or not yet: 27
- Read on: November 19, 2026

## Trials

The 25 newest of 51, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 20, 2026 | NCT07715630 | In Vivo PICX CAR-T Therapy for R/R Multiple Myeloma | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Relapsed or Refractory Multiple Myeloma (RRMM) | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715630) |
| June 10, 2026 | NCT07637929 | Non-Interventional Study of Puzol-cel for CD19-Positive Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia | Chongqing Precision Biotech Co., Ltd | Observational | Not yet recruiting | Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia (r/r B-ALL) | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07637929) |
| March 6, 2026 | NCT07456371 | PIC1 Injection Therapy for Relapsed/Refractory B-NHL | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Non-Hodgkin Lymphoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07456371) |
| February 11, 2026 | NCT07403097 | Study of CD19 CAR-T Therapy for Refractory SLE | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Systemic Lupus Erythematosus | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07403097) |
| January 12, 2026 | NCT07331467 | Study of Ultra-Fast CD19 CAR-T Therapy for Refractory SLE | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Systemic Lupus Erythematosus | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07331467) |
| January 5, 2026 | NCT07318259 | Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Systemic Lupus Erythematosus | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07318259) |
| November 20, 2025 | NCT07239323 | In VIVO CAR-T Therapy for Relapsed/Refractory Hematological Malignancies | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | B-Acute Lymphoblastic Leukemia, B Cell Non-Hodgkin's Lymphoma, Multiple Myeloma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07239323) |
| September 19, 2025 | NCT07184450 | Clinical Study of BCMA/CD70-targeted CAR-T Therapy for Refractory Pediatric Rheumatic Diseases | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Juvenile Dermatomyositis (JDM), Polyarticular Juvenile Idiopathic Arthritis, Systemic Sclerosis (SSc), Primary... | 11 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07184450) |
| September 18, 2025 | NCT07181720 | CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors | Chongqing Precision Biotech Co., Ltd | Phase 1 | Suspended | Renal Cell Carcinoma (RCC), Lung Cancer, Anaplastic Thyroid Carcinomas, Ovarian Cancer, Cervical Cancer, Thymic... | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07181720) |
| September 18, 2025 | NCT07179692 | CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Lung Cancer, Gastric Cancer, Colon Cancer, Rectal Cancer, Esophageal Cancer, Pancreas Cancer | 108 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07179692) |
| May 28, 2025 | NCT06992583 | Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Advanced Lung Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06992583) |
| April 25, 2025 | NCT06945523 | Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Advanced Lung Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06945523) |
| April 3, 2025 | NCT06909474 | Clinical Trial of CD5-targeted CAR-NK Therapy for Relapse/Refractory T-Cell Hematologic Malignancies | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | T-ALL/Lymphoma | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06909474) |
| March 30, 2025 | NCT06903117 | Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Advanced Lung Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06903117) |
| March 24, 2025 | NCT06892145 | Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Systemic Lupus Erythematosus (SLE), Refractory | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06892145) |
| January 10, 2025 | NCT06768151 | A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Advanced Lung Cancer | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06768151) |
| November 15, 2024 | NCT06690827 | Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/Refractory AML or BPDCN | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | AML (Acute Myeloid Leukemia), BPDCN (Blastic Plasmacytoid Dendritic Cell Neoplasm) | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06690827) |
| November 13, 2024 | NCT06686524 | Clinical Study of CD19 Targeted Universal Chimeric Antigen Receptor T Lymphocytes (UCAR-T) for the Treatment of Refractory Juvenile... | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Dermatomyositis, Juvenile, Dermatomyositis | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06686524) |
| October 15, 2024 | NCT06641024 | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL | Chongqing Precision Biotech Co., Ltd | Phase 1 | Not yet recruiting | Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06641024) |
| August 26, 2024 | NCT06569472 | Clinical Trial of CD19-targeted CAR-T Therapy for Refractory Juvenile Dermatomyositis | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Juvenile Dermatomyositis | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06569472) |
| January 22, 2024 | NCT06215950 | A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Ovarian Cancer, Cervix Cancer, Metastatic Cancer, Advanced Cancer, Gynecologic Cancer | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06215950) |
| December 22, 2023 | NCT06180174 | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/Refractory B Cell Lymphoma | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | B Cell Lymphoma, Non Hodgkin Lymphoma | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06180174) |
| November 13, 2023 | NCT06126406 | Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes（CAR-T） for CEA Positive Advanced Malignant Solid Tumors | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Gastric Cancer, Colon Cancer, Rectal Cancer, Breast Cancer, Lung Cancer, Esophagus Cancer, Cholangiocarcinoma, Pancreas... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06126406) |
| September 28, 2023 | NCT06056921 | Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease | Chongqing Precision Biotech Co., Ltd | Phase 1 | Unknown | SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma, Dermatomyositis, Anti-Neutrophil Cytoplasmic... | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06056921) |
| September 21, 2023 | NCT06043466 | A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors | Chongqing Precision Biotech Co., Ltd | Phase 1 | Recruiting | Colorectal Cancer, Esophagus Cancer, Gastric Cancer, Pancreas Cancer, Non-small Cell Lung Cancer, Breast Cancer, Bile... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06043466) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 34 |
| Phase 1/2 | 15 |
| Phase 2 | 1 |
| Observational | 1 |

## By status

| Status | Trials |
| --- | --- |
| Recruiting | 25 |
| Unknown | 18 |
| Completed | 4 |
| Not yet recruiting | 2 |
| Suspended | 1 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Stomach Neoplasms | 8 |
| Pancreatic Neoplasms | 8 |
| Esophageal Neoplasms | 7 |
| Lymphoma, B-Cell | 6 |
| Multiple Myeloma | 6 |
| Lung Neoplasms | 6 |
| Neoplasm Metastasis | 6 |
| Leukemia | 5 |
| Lupus Erythematosus, Systemic | 5 |
| Breast Neoplasms | 5 |
| Colonic Neoplasms | 5 |
| Carcinoma, Renal Cell | 5 |
| Ovarian Neoplasms | 5 |
| Uterine Cervical Neoplasms | 5 |
| Leukemia, Myeloid, Acute | 4 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 |
| Dermatomyositis | 4 |
| Leukemia, B-Cell | 4 |
| Rectal Neoplasms | 4 |
| Colorectal Neoplasms | 3 |
| Lymphoma, Non-Hodgkin | 3 |
| Neoplasms, Plasma Cell | 3 |
| Recurrence | 3 |
| Blastic Plasmacytoid Dendritic Cell Neoplasm | 2 |
| Scleroderma, Systemic | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Investment management firms in the United States](https://specstream.ai/data/businesses/investment-management-firms/united-states)
- [Ecuadorian restaurants in the United States](https://specstream.ai/data/businesses/ecuadorian-restaurants/united-states)
- [B2B signage companies in the United States](https://specstream.ai/data/businesses/b2b-signage-companies/united-states)
- [Telephone service providers in the United States](https://specstream.ai/data/businesses/telephone-service-providers/united-states)
- [Payroll companies in the United States](https://specstream.ai/data/businesses/payroll-companies/united-states)
- [Hotels in the United States](https://specstream.ai/data/businesses/hotels/united-states)
